相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Rudolf M. Huber et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang et al.
LANCET RESPIRATORY MEDICINE (2020)
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Janna Josephus Anna Oda Schoenmaekers et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Safety issues with the ALK inhibitors in the in the treatment of NSCLC: A systematic review
Loay Kassem et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis
Tamio Okimoto et al.
INTERNAL MEDICINE (2019)
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Byoung Chul Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
1487PDIntracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting
D R Camidge et al.
ANNALS OF ONCOLOGY (2019)
Leptomeningeal metastases in non-small-cell lung cancer
Haiying Cheng et al.
LANCET ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
Fausto Petrelli et al.
PLOS ONE (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)
Byoung Chul Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis
Kimberly L. Johung et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M. Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Paula Mulvenna et al.
LANCET (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
Deepa Rangachari et al.
LUNG CANCER (2015)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Leptomeningeal carcinomatosis: Prognostic value of clinical, cerebrospinal fluid, and neuroimaging features
Jose-Alberto Palma et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2013)
Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases
A. Ali et al.
CURRENT ONCOLOGY (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors
Su Jin Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era
Jin Hyun Park et al.
LUNG CANCER (2012)
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Management and Prognosis in Synchronous Solitary Resected Brain Metastasis from Non-Small-Cell Lung Cancer
Alexander V. Louie et al.
CLINICAL LUNG CANCER (2009)
Multidisciplinary management of brain Metastases
April F. Eichler et al.
ONCOLOGIST (2007)
Time from treatment to subsequent diagnosis of brain, metastases in stage III non-small-cell lung cancer: A retrospective review by the southwest oncology group
LE Gaspar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Current management of brain metastases, with a focus on systemic options
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Pronostic factors of synchronous brain metastases from lung cancer
N Penel et al.
LUNG CANCER (2001)
分享论文
